Rituximab alone proves effective in the treatment of refractory, severe stage III AIDS-related non-Hodgkin's paediatric lymphoma.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000209:etiology*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab